Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: Experience in breast cancer Journal Article
| Authors: | Gomez, P.; Lacouture, M. E. |
| Article Title: | Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: Experience in breast cancer |
| Abstract: | Current combination therapies for advanced breast cancer provide a modest survival benefit but with greater toxicity than with monotherapies. New combinations are needed that improve the efficacy of current treatments and have acceptable tolerability profiles. Recent clinical trials have assessed the efficacy and safety of the multikinase inhibitor sorafenib in combination with common treatments for advanced breast cancer. Sorafenib has both antiangiogenic and antiproliferative activities and is indicated for patients with unresectable hepatocellular and advanced renal cell carcinoma. Generally, sorafenib is associated with manageable, non-life-threatening adverse events. One of the more common adverse events seen with sorafenib is hand-foot skin reaction, a dermatologic toxicity usually localized to the pressure points of the palms and soles. Although hand-foot skin reaction is reversible and not life threatening, it can have a significant impact on a patient's quality of life and may necessitate dose modification. Moreover, sorafenib is being evaluated in combination with breast cancer treatments that are associated with a similar dermatologic toxicity (e.g., capecitabine-induced hand-foot syndrome). This review looks at the use of sorafenib in combination with selected chemotherapies in patients with advanced breast cancer and considers the incidence, prevention, and management of hand-foot skin reaction. © AlphaMed Press. |
| Keywords: | cancer chemotherapy; clinical feature; disease course; fatigue; neutropenia; review; sorafenib; bevacizumab; placebo; advanced cancer; cancer combination chemotherapy; diarrhea; drug dose reduction; drug safety; drug withdrawal; hypertension; hypophosphatemia; liver cell carcinoma; monotherapy; side effect; treatment duration; benzenesulfonates; pyridines; skin manifestation; capecitabine; gemcitabine; paclitaxel; cell proliferation; disease association; carboplatin; melanoma; progression free survival; drug eruption; liver toxicity; multiple cycle treatment; nephrotoxicity; breast cancer; anemia; bone marrow suppression; gastrointestinal symptom; leukopenia; mucosa inflammation; nausea; stomatitis; thrombocytopenia; antineoplastic combined chemotherapy protocols; myalgia; peripheral neuropathy; incidence; weight reduction; steroid; antineoplastic activity; breast neoplasms; kidney carcinoma; docetaxel; arthralgia; asthenia; drug dose escalation; drug fever; dyspnea; loading drug dose; chemotherapy induced emesis; skin exfoliation; survival time; disease severity; celecoxib; disease duration; letrozole; drug blood level; drug cytotoxicity; anastrozole; hand foot syndrome; alopecia; fluocinonide; tazarotene; phase 2 clinical trial (topic); phase 3 clinical trial (topic); disease activity; phase 1 clinical trial (topic); hand-foot skin reaction; hand-foot syndrome; pyridoxine |
| Journal Title: | The Oncologist |
| Volume: | 16 |
| Issue: | 11 |
| ISSN: | 1083-7159 |
| Publisher: | Oxford University Press |
| Date Published: | 2011-01-01 |
| Start Page: | 1508 |
| End Page: | 1519 |
| Language: | English |
| DOI: | 10.1634/theoncologist.2011-0115 |
| PROVIDER: | scopus |
| PUBMED: | 22016478 |
| PMCID: | PMC3233284 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 3 January 2012" - "CODEN: OCOLF" - "Source: Scopus" |
